C

CSL

Develops and delivers biotherapies and vaccines

Hospital Relations Manager, Coagulation and Respiratory

Full-TimePosted on 10/21/2026
No salary listed
Expert
Bachelor's
France
In PersonSector covers Bretagne, Pays de la Loire, and Centre, France.
Sales & Account ManagementField Sales

About the job

Requirements
  • A minimum Bac + 3 qualification in a commercial and/or scientific field.
  • A medical-visit diploma or an equivalent qualification attested by AGVM is required.
  • At least 8–10 years of experience as a hospital sales representative in scientific specialties and complex environments.
  • Successful experience promoting products intended exclusively for hospitals.
  • In-depth knowledge of hospital internal pathways and the hospital environment.
  • Knowledge of pharmaceutical and hospital regulations and the promotional information charter.
  • Understanding of the competitive environment, specialties, marketing authorizations, packaging, and product use.
  • Scientific and medical knowledge of hospital specialties.
  • Communication, information, negotiation, information-transfer, and meeting-facilitation techniques.
  • Partnership-development techniques.
  • Understanding of healthcare economics, including medical economics and pharmacoeconomics.
  • Knowledge of hospital prescribing practices.
  • Proficiency in sales techniques.
  • Ability to work in a team.
  • Proficiency with Microsoft Office, Outlook, the current customer relationship management system, and QlikView sales analysis tools.
  • Technical English.
Responsibilities
  • Contribute to quantitative and qualitative objectives for the Coagulation and Respiratory network, ensuring appropriate use at healthcare institutions in compliance with internal rules and applicable law.
  • Maintain CSL's image as a preferred partner in its areas of expertise.
  • Own assigned sector sales-volume and revenue targets and develop sales of CSL specialties in Coagulation and Respiratory in that sector.
  • Prepare conditions for tenders and understand their decision-making process.
  • Deliver and monitor execution of the sector action plan.
  • Promote assigned specialties to healthcare professionals.
  • Share information and collaborate cross-functionally with the sector team to coordinate actions with healthcare professionals in line with the action plan.
  • Build trusted client relationships by identifying needs relevant to CSL's products and services.
  • Share client information with management, the sector team, and relevant departments; maintain a list of key hospital clients.
  • Contribute to commercial tactics and guide the sector team's action priorities.
  • Provide healthcare professionals with information about promoted specialties, CSL's quality policy, and CSL's ethics rules in compliance with applicable regulations and internal procedures.
  • Communicate product information, current indications, safety data, and appropriate-use information using only approved promotional or institutional materials.
  • Communicate CSL's ethics rules and inform healthcare professionals of their rights concerning personal data processed by CSL.
  • Conduct in-person and/or remote visits and meetings with healthcare professionals in accordance with the visited departments' organizational rules.
  • Prepare, conduct, and facilitate hospital medical-information meetings and regional expert meetings with opinion leaders and other healthcare professionals.
  • Supervise guests and staff stands at regional, national, and/or international congresses.
  • Maintain the scientific knowledge required for the role by participating in company training and assessments and using available resources.
  • Where applicable, follow up on CSL clinical studies at centers that are already open.
  • Develop the sector action plan, prioritize tactical actions for healthcare professionals, and support hospital formulary listing of assigned specialties.
  • Ensure appropriate use with pharmacists responsible for blood-derived medicinal products.
  • Work actively with the National Sales Director and the sector's RGC.
  • Propose and monitor allocation of resources for identified clients.
  • Track and analyze monthly sales for assigned specialties and promptly report analyses to the National Sales Director using approved tools.
  • Monitor competitors and share relevant information with appropriate departments.
  • Understand treatment-selection decision processes and develop ethical client relationships in compliance with the promotional information charter.
  • Tailor product and service arguments to the healthcare professionals visited.
  • Share and reconcile client data with colleagues and internal departments to support quality professional relationships.
  • Coordinate with internal resources to respond to client needs, campaign feedback, new needs, and expense monitoring.
  • Promptly transmit pharmacovigilance information, quality complaints, and medical-information questions in accordance with regulatory and internal CSL requirements.
  • Use the customer relationship management system and other management-designated information-sharing tools daily.
  • Plan and report medical-visit activity, including reports, appointments, and expenses.
  • Follow all communicated internal procedures and monitor the investment budget and related activities.
  • Act as the expert on sector accounts and clients regarding sales opportunities, analyze gaps between targets and results, interpret and report monthly sales data to management, and promptly propose corrective actions.
Desired Qualifications
  • Knowledge of plasma-derived medicines and recombinant analogues is an advantage.

About the company

CSL is a global biotechnology company that develops and delivers biotherapies and influenza vaccines. It focuses on plasma-derived and recombinant therapies for rare and serious diseases and sells to healthcare providers, hospitals, and governments across the Americas, Asia Pacific, and Europe. Its product range includes treatments for rare diseases, influenza vaccines, and antivenoms, produced through its R&D, manufacturing, and distribution operations. CSL differentiates itself by offering the broadest portfolio of plasma-derived and recombinant therapies and by leveraging its global footprint and emphasis on diversity to reach diverse markets. The company’s main goal is to save lives and protect health by expanding access to high-quality therapies and vaccines worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Parkville, Australia

Founded

1916

Get referred to CSL

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • CSL reported US$176 million FY26 cost savings, ahead of its transformation target.
  • US military flu-vaccine exceptions restored some demand after April 2026 mandate cuts.
  • VarmX’s 2029 coagulation program gives CSL a new high-value pipeline beyond plasma.

What critics are saying

  • FY26 statutory loss hit US$2.6 billion after US$7.1 billion impairments and restructuring.
  • CSL plans US$400 million FY27 savings, implying more closures, layoffs, and execution friction.
  • The U.S. plasma turnaround depends on Horizon 2; failure risks long-term margin collapse.

What makes CSL unique

  • CSL’s FY26 revenue reached US$15.8 billion across plasma, vaccines, and Vifor.
  • Seqirus’ AUJEMFLU won UK and European approvals, backed by Lancet Phase 3 data.
  • HEMGENIX remains Europe’s first approved hemophilia B gene therapy, strengthening CSL Behring.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Time Off
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

1%
PR Newswire
Oct 21st, 2026
CSL appoints ViiV Healthcare chief Deborah Waterhouse as CEO on $1.9M base salary

CSL Limited has appointed Deborah Waterhouse as chief executive officer and managing director, effective February 1, 2027. The board's decision followed a global search and was unanimous. Waterhouse has led ViiV Healthcare, an HIV specialist majority owned by GSK, since 2017. ViiV had sales of £7.7 billion in GSK's 2025 financial year. She also serves as president of GSK Global Health and previously ran GSK's US vaccines and primary care businesses. Her base salary will be £1,500,000 a year. She will stay based in the UK. Gordon Naylor will remain interim chief executive until then, before returning to the board as a non-executive director.

Yahoo Finance
Oct 8th, 2026
CSL to roll out Haemonetics' NexSys devices across all US plasma centres by end of 2027

Haemonetics shares jumped 12% after the company announced CSL now expects to move all of its current US plasma collection centres to Haemonetics' NexSys devices by the end of 2027. The deal, first disclosed in August, was initially limited to only a portion of CSL's US centres with no timeline. The expanded agreement is significant because losing CSL previously flattened Haemonetics' growth. In fiscal 2026, the company's organic revenue growth was just 1.1%, compared to 9.5% excluding lost CSL sales. Following the surge, Haemonetics trades at approximately 21 times forward earnings, above its five-year average of 19.1 times. The deal is non-exclusive with no minimum purchase requirements, meaning CSL can still modify scope and timing. Management plans to provide further details during its November earnings call.

Pharma Dispatch
Oct 6th, 2026
CSL raises $1.5B from US bond investors to refinance debt

CSL has raised US$1.5 billion through corporate bonds issued in the United States to refinance existing debt. The Australian biotechnology company turned to offshore debt markets for the transaction. The bond issuance allows CSL to manage its capital structure by replacing current borrowings with new financing secured from US investors.

CSL
Sep 21st, 2026
CSL partners with VarmX in a strategic collaboration and option agreement to develop first-in-class investigational coagulation treatment

Melbourne, Australia – 16 September 2025 CSL today announced it has entered into a strategic collaboration with privately held Dutch biotech company VarmX BV to support the company’s...

PR Newswire
Sep 10th, 2026
CSL Seqirus' triple-enhanced flu vaccine shows superior protection for older adults in Lancet study

CSL Seqirus has published Phase 3 study results in The Lancet Infectious Diseases for its MF59-adjuvanted cell-based higher-dose quadrivalent influenza vaccine for older adults. The vaccine, marketed as AUJEMFLU, combines three proven approaches: MF59 adjuvant, cell-based manufacturing, and higher-dose formulation. The randomised study enrolled 7,699 adults aged 50 and older across eight countries. Results demonstrated superiority versus an adjuvanted egg-based comparator across all four influenza strains and age groups. The vaccine showed non-inferiority versus a recombinant vaccine for three of four strains in the 50-plus age group and all four strains in those aged 65-plus. The trivalent formulation received approval from the UK's MHRA and the European Commission earlier this year for adults aged 50 and above. Regulatory submissions have been made in multiple markets.